Cardiology has found a second wind in the 2026 radiopharmaceutical boom. While oncology initially drove the market, the development of ultra-fast decay cardiac tracers has allowed for real-time inflammation mapping of the heart wall. This is particularly vital in the post-pandemic era, where sub-clinical myocarditis is being monitored with increasing regularity in urban centers across the...
Tiếng Việt 
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)